Skip to main navigation
Skip to main content
Skip to Footer
English
Français
Canada
Répertoire du site Sandoz
Our Work
What We Do
Quality Generics
Biopharmaceuticals
Specialty Products
About Us
Who We Are
Corporate Responsibility
Doing Business Responsibly
Contact Us
Grants, Donations and Sponsorships
Products
Consumers
Patients
Healthcare Professionals
Patient Support Programs
News
Media Releases
Media Resource Center
Stay Up-To-Date
Careers
Available Positions
Diversity & Inclusion
Our Benefits
Sandoz-Connect Portal
Search
Global Impact
Medicines
Discovery
Hope
Global Impact
Education & Awareness
Global Impact
Subscribe
Sandoz Canada improves patients’ access to treatment with the launch of three new generics
Sandoz Canada Launches PrSandoz® Sitagliptin and PrSandoz® Sitagliptin-Metformin
Novartis expands humanitarian efforts in Ukraine through donation of essential medicines
Sandoz Canada Completes Sale of Sterile Injectable Medicine Manufacturing Plant
Sandoz Canada launches PrSandoz® Dimethyl Fumarate Delayed-Release Capsules, a generic equivalent to PrTecfidera*
Sandoz Canada launches PrSandoz® Lenalidomide, a generic equivalent to PrRevlimid®
Accessa and Québec owner-pharmacists make their debut in the Patient Support Program sector with Sandoz Canada's Hyrimoz
Sandoz Canada launches its 6th biosimilar with PrInclunox® and PrInclunox® HP
A first in Canada: generic version of pirfenidone
1 of 4
››
